Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma
Abstract Elranatamab, an approved bispecific antibody (BsAb) for relapsed/refractory multiple myeloma, forms an immune synapse between the T-cell CD3 marker and B-cell maturation antigen (BCMA) on myeloma cells. Circulating soluble BCMA (sBCMA) is associated with disease burden and may reduce drug e...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Portfolio
2025-09-01
|
| coleção: | npj Systems Biology and Applications |
| Acesso em linha: | https://doi.org/10.1038/s41540-025-00585-z |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|